Roth Capital Partners has initiated coverage of HeartBeam Inc. (NASDAQ: BEAT) with a Buy rating and a $4 price target, emphasizing the company's near-term catalyst of expected FDA clearance for its 12-lead ECG synthesis software. The report highlights HeartBeam's compact, credit card-sized, cable-free device that can synthesize a full 12-lead ECG, positioning it as a breakthrough in remote cardiac monitoring. Roth's analysts, led by Kyle Bauser, Ph.D., view BEAT as undervalued given its strong clinical validation, lean cost structure, and potential to redefine arrhythmia detection and treatment in decentralized care environments.
The initiation note underscores that HeartBeam's pivotal VALID-ECG study (n=198) demonstrated a 93.4% diagnostic agreement between its synthesized ECG and standard 12-lead systems, supporting reliability in arrhythmia assessment. FDA clearance for the synthesis software is anticipated by the end of 2025, enabling a targeted commercial rollout in concierge and preventive cardiology markets before wider adoption. Roth's model projects profitability by 2027 and estimates revenue of $20 million by 2028, supported by 70% gross margins and scalable recurring revenue streams.
Roth Capital applied a 9x EV/sales multiple to its FY28 estimate, discounted two years at 10%, to arrive at the $4 target. The firm compared HeartBeam's valuation potential to precedent transactions such as Preventice Solutions' $1.2 billion acquisition (8x LTM sales) and BioTelemetry's $2.8 billion buyout (6x LTM sales). Roth concludes that BEAT's AI-driven diagnostic precision, regulatory readiness, and first-mover advantage in 12-lead remote monitoring position it as a compelling opportunity within the high-growth medical technology and digital health sectors. To view the full report, visit https://ibn.fm/FcW8B.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The 12-Lead ECG synthesis software is under FDA review. The Company holds over 20 issued patents related to technology enablement. For the latest news and updates relating to BEAT, visit the company's newsroom at https://ibn.fm/BEAT.
